Skip to main content
Monday, November 16, 2026Nov 16

CVS stops sale of heartburn drugs with suspect contaminant

FILE- In this Aug. 7, 2018, file photo a CVS Pharmacy building sign rests on a Jackson, Miss., store.  CVS Health topped fourth-quarter earnings forecasts, but the nation’s second-largest drugstore chain also debuted a 2019 outlook that fell far short of Wall Street expectations. The company said Wednesday, Feb. 20, 2019,  that it expects adjusted earnings to range between $6.68 and $6.88 this year. FactSet says analysts expect earnings of $7.35 per share. (AP Photo/Rogelio V. Solis, File)
FILE- In this Aug. 7, 2018, file photo a CVS Pharmacy building sign rests on a Jackson, Miss., store. CVS Health topped fourth-quarter earnings forecasts, but the nation’s second-largest drugstore chain also debuted a 2019 outlook that fell far short of Wall Street expectations. The company said Wednesday, Feb. 20, 2019, that it expects adjusted earnings to range between $6.68 and $6.88 this year. FactSet says analysts expect earnings of $7.35 per share. (AP Photo/Rogelio V. Solis, File)

CVS has halted sales of popular heartburn treatment Zantac and its generic store brand after warnings by U.S. health regulators.

It’s the latest precautionary move by retailers and manufacturers after the U.S. Food and Drug Administration recently warned consumers about a potentially dangerous contaminant in prescription and over-the-counter versions of Zantac.

In its announcement this weekend, CVS said customers who bought Zantac products can return them for a refund. The retailer will continue to sell other heartburn medications.

WHAT’S THE ISSUE?

In September, the FDA said it detected low levels of a probable cancer-causing chemical known as NDMA in Zantac and related generic drugs to treat ulcers and reflux disease. The same chemical has been linked to dozens of recalls of prescription blood pressure drugs in the past year.